Locations:
Search
Anti-IL-6 and anti-IL-1 agents: Center stage for COVID-19 stage 3 disease
The search for new therapeutic targets
If denosumab is stopped, it should be replaced with another osteoporosis treatment
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
TNF alpha inhibitors: cutaneous side effects and management strategies
Management pearls from a new expert review
Sustained efficacy and safety
Varied platforms maximize opportunities for interactive, problem-based learning
Behavioral modifications to reduce severity of symptoms
Defect in myosin binding may explain why a significant percentage of patients do not adequately respond to anti-TNF therapy
Advertisement
Advertisement
